Parnax Lab Ltd

Parnax Lab Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s near- to medium-term outlook.

At Rs 104.00, sellers were still queuing — but there were no buyers willing to take the other side. Parnax Lab Ltd locked at its lower circuit of 20% on 09 Sep 2026, with unfilled sell orders and a frozen price, signalling a severe imbalance in supply and demand.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 September 2026. This revision reflects a combination of deteriorating technical indicators, subdued financial performance, and valuation concerns, despite some long-term growth achievements. The company’s Mojo Score now stands at 26.0, signalling heightened caution for investors.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Strong Sell to Sell as of 1 September 2026. This adjustment reflects a complex interplay of technical signals, valuation metrics, financial trends, and overall quality assessments, signalling caution for investors despite some positive price momentum.

Parnax Lab Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 17 Aug 2026. This revision reflects deteriorating financial trends, weakening technical indicators, and valuation concerns, signalling caution for investors amid a challenging operating environment.

Parnax Lab Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 01 August 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This revision follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, reflecting a cautious stance despite some positive long-term returns.

Parnax Lab Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical outlook and valuation metrics despite flat recent financial performance. The upgrade, effective from 13 July 2026, is driven by a combination of bullish technical indicators, attractive valuation relative to peers, stable financial trends, and a consistent return profile that outpaces broader market benchmarks.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 July 2026. This change reflects a combination of flat recent financial performance, mixed technical indicators, and valuation considerations that collectively weigh on the stock’s near-term outlook despite its strong long-term returns.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 3 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some recent flat quarterly performance. The stock’s recent market-beating returns and enhanced technical outlook have contributed to this reassessment.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a recent downgrade in its Mojo Grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value-oriented investors seeking exposure in this sector.